Sucanon®…Diabetes is not curable but is treatable…enjoy life™
What is Sucanon®?:
Sucanon® is one of only several drugs approved in the world, belonging to a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.
- Type I Diabetes (previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes): results from the body’s failure to produce insulin, and presently requires the person to inject insulin.
- Type II Diabetes (previously called non-insulin-dependent diabetes mellitus (NIDDM) or maturity-onset diabetes): results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes combined with an absolute insulin deficiency.
In 2000, according to the World Health Organization, at least 171 million people worldwide suffer from diabetes, or 2.8% of the population.
The incidence of diabetes mellitus in Mexico will have risen 40% by the year 2012, killing over 100,000 Mexicans during that year, according to Jose Angel Cordova Villalobos, Health Secretary, Mexico.
Only 68 percent of U.S. diabetics are diagnosed, according to the American Diabetes Association, an advocacy group based in Alexandria, Virginia. Some 5.7 million Americans don’t know they have the disease, the association said.
PharmaRoth Labs, Inc. Announces Mexican Distributor Surpasses Sales Goal
Media Advertising Increases as Sales Growth Exceeds Contractual Obligation
LAS VEGAS, NV–(Marketwired – Apr 16, 2014) – PharmaRoth Labs, Inc. (OTC Pink: ROTH) (PINKSHEETS: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today that Marcas de Renombre (MDR), the company’s exclusive distributor in Mexico has surpassed their first year minimum sales goal. In addition, the company is pleased to confirm that media advertising in Mexico is concurrently increasing.
“I am very excited to announce that our distributor in Mexico has exceeded the contractual obligation of $480,000 of purchased product this quickly,” said Luis Lopez, CEO of PharmaRoth. “The Agreement called for this minimum to be bought in the initial year in order to maintain exclusive status. The sales are media driven and even though the approval for the advertising from the Ministry took much longer than anticipated, sales has been accelerated now that the budget from MDR towards Sucanon® has been increased to meet the demand.”
Lopez continues: “As previously announced, our proprietary Type II Diabetes drug is being sold thru retail and wholesale channels backed by aggressive media advertising all throughout Mexico. The product has never enjoyed this level of availability in any market before so it is hugely exciting to be able to provide a safe and effective drug for those afflicted with such a serious disease.”
For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at www.pharmaroth.com
PharmaRoth Labs, Inc. (OTC: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth’s strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.